InvestorsHub Logo
Post# of 4973042
Next 10
Followers 57
Posts 19762
Boards Moderated 1
Alias Born 02/16/2008

Re: None

Monday, 12/07/2009 3:40:14 PM

Monday, December 07, 2009 3:40:14 PM

Post# of 4973042
BiomedReports: News and FDA Updates for Health Sciences Group (OTC:HESG), Hospira (NYSE:HSP), ICON (NASDAQ:ICLR)

Pasadena, CA, Dec 07, 2009 (M2 PRESSWIRE via COMTEX) -- BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com

On 04/12/09, Health Sciences Group, Inc. (OTC:HESG) would like to announce that it is in strong negotiations to acquire a minority stake in two separate Montana-based marijuana growing, distribution and care giving operations.

On 04/12/09, Hospira, Inc. (NYSE:HSP), a leading global specialty pharmaceutical and medication delivery company, announced the launch of its next-generation 50 mL and 100 mL VisIV(TM) containers for intravenous (I.V.) medications and solutions, and now offers a complete size range (50 mL to 1 L) of the award-winning, environmentally responsible VisIV product.

On 04/12/09, ICON plc, (NASDAQ:ICLR) announced it has received a warning letter from the U.S. Food and Drug Administration (FDA) regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006.

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

CONTACT: M. Davila, Editor, BioMedReports.Com e-mail: support@biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

(C)1994-2009 M2 COMMUNICATIONS

**********************************************************************

As of Thursday, 12-03-2009 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated an UPTREND on 03-16-2009 for HSP @ $25.10.

For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2009 Comtex News Network, Inc. All rights reserved.

-0-

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.